Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done?

Area of Science:

• Paediatric infectious diseases
• Clinical trial design
• Tuberculosis research

Background:

• Traditional paediatric tuberculosis trials focus on pharmacokinetics and safety, extrapolating efficacy from adults.
• There's a growing need for paediatric-specific efficacy trials, especially for multidrug-resistant tuberculosis (MDR-TB).
• Current MDR-TB treatments for children are lengthy and toxic, necessitating evaluation of novel, safer regimens.

Purpose of the Study:

• To highlight the necessity and challenges of conducting paediatric MDR-TB efficacy trials.
• To explore optimal trial designs, considering diagnostic uncertainty and disease spectrum in children.
• To advocate for the urgent development and evaluation of improved MDR-TB treatment regimens for paediatric populations.

Main Methods:

• Discussion of traditional trial limitations and the evolving recognition of the need for paediatric efficacy studies.
• Analysis of challenges in defining inclusion criteria, particularly regarding confirmed MDR-TB diagnosis and drug resistance profiles.
• Exploration of alternative trial designs, such as non-inferiority trials focusing on safety superiority.

Main Results:

• Paediatric MDR-TB efficacy trials are complex due to diagnostic variability and the need for generalizable results.
• Current MDR-TB treatments in children have acceptable outcomes, making superiority trials potentially suboptimal.
• Designing standardized yet adaptable treatment regimens for diverse paediatric TB presentations is a significant challenge.

Conclusions:

• Paediatric MDR-TB efficacy trials are urgently required to evaluate shorter, safer treatment regimens.
• Careful consideration of inclusion criteria and trial design is crucial for generalizability and ethical conduct.
• Global collaboration and capacity building are key to making these essential trials feasible and successful.